Callan Family Office LLC Buys New Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Callan Family Office LLC has acquired a new stake in Jazz Pharmaceuticals PLC, purchasing 5,833 shares valued at approximately $619,000 in the second quarter.
• Analyst ratings for Jazz Pharmaceuticals have been largely positive, with Goldman Sachs raising their price objective from $162 to $185, indicating strong buy sentiments from multiple firms.
• Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals, marking a 1.38% decrease in his ownership, while insiders have collectively sold 11,500 shares within the last ninety days.

Callan Family Office LLC bought a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 5,833 shares of the specialty pharmaceutical company's stock, valued at approximately $619,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Hurley Capital LLC bought a new stake in Jazz Pharmaceuticals during the 1st quarter valued at approximately $25,000. Picton Mahoney Asset Management boosted its stake in Jazz Pharmaceuticals by 2,445.5% during the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after purchasing an additional 269 shares during the period. Spire Wealth Management boosted its stake in Jazz Pharmaceuticals by 137.6% during the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after purchasing an additional 161 shares during the period. SVB Wealth LLC bought a new stake in Jazz Pharmaceuticals during the 1st quarter valued at approximately $36,000. Finally, Geneos Wealth Management Inc. boosted its stake in Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 137 shares during the period. Institutional investors own 89.14% of the company's stock.

Insider Activity

In other news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares of the company's stock, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders sold 11,500 shares of company stock valued at $1,525,280. Corporate insiders own 4.30% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on JAZZ shares. The Goldman Sachs Group raised their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research report on Friday, August 29th. Morgan Stanley raised their price objective on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 24th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a research report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price objective for the company. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $178.93.

Jazz Pharmaceuticals Trading Down 0.2%

Shares of JAZZ opened at $135.14 on Tuesday. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The stock has a 50 day simple moving average of $126.25 and a 200-day simple moving average of $115.66. The stock has a market cap of $8.20 billion, a PE ratio of -20.08, a PEG ratio of 8.32 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company posted $5.30 earnings per share. The company's quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.